BlossomHill Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12
SAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biopharmaceutical company focused on the design and development of next-generation medicines for cancer, today announced the company will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 2:00 p.m. PT.
J. Jean Cui, Ph.D., President & Chief Executive Officer, and Geoff Oxnard, M.D., Chief Medical Officer, will provide an overview of the company’s pipeline, including BH-30643, a first-in-class, macrocyclic, CNS-active, mutant-selective OMNI-EGFR™ inhibitor currently being evaluated in the Phase 1/2 SOLARA trial for EGFR-mutant non-small cell lung cancer (NSCLC). BlossomHill is also advancing BH-30236, a novel macrocyclic CLK inhibitor targeting aberrant RNA splicing, an important driver of disease progression and therapeutic resistance across multiple cancer types.
About BlossomHill Therapeutics
BlossomHill Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company focused on designing and developing next-generation targeted therapies for cancer. Founded and led by industry veteran J. Jean Cui, Ph.D., with her proven track record in oncology drug design and development – including three FDA-approved drugs – BlossomHill applies cutting-edge science to address key oncogenic drivers and improve patient outcomes in difficult-to-treat cancers. The company’s lead clinical programs include BH-30643, a first-in-class, macrocyclic, non-covalent, mutant selective OMNI-EGFR™ inhibitor for the treatment of EGFR- or HER2-mutated non-small cell lung cancer (NSCLC), and BH-30236, a macrocyclic CLK inhibitor for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML) or higher-risk myelodysplastic syndrome (HR-MDS), representing a first-in-class opportunity. BlossomHill Therapeutics is headquartered in San Diego, California and has raised a total of $257 million from leading life sciences investors. For more information, visit bhtherapeutics.com and follow us on LinkedIn and X.
Contacts:
Media:
Ashlea Kosikowski
1AB
ashlea@1abmedia.com
Investors:
Steve Klass
1AB
steve@1abmedia.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
